Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Earnings Data
Report Date
Apr 30, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.28Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong set of early biologic and hematologic signals at the 20 mg dose — substantial HbF induction (+12.2% absolute), doubled F-cell percentages, marked reductions in hemolysis markers (LDH -34%, indirect bilirubin -40%), reticulocyte decline (-42%), and a ~1.1 g/dL hemoglobin increase — alongside an acceptable short-term safety profile and a clear regulatory path forward. Major caveats are small sample size, short duration (12 weeks), assay missingness/variability, and that clinical endpoints (VOCs, long-term durability, broader safety) remain exploratory and unproven. On balance the data are encouraging and support advancing to a potential registration-enabling study, while recognizing the need for larger, longer trials to confirm clinical benefit and durability.Company Guidance
Comparative Potential vs. Standard of Care
Pociredir 20 mg HbF and F-cell levels at 12 weeks (~20% HbF, ~60% F cells) are comparable to the highest quartile responders to hydroxyurea (which averaged ~10% HbF and ~35% F cells overall), suggesting potential to be a best-in-class oral HbF inducer.
Robust HbF Induction at 20 mg
Mean fetal hemoglobin (HbF) increased from 7.1% baseline to 19.3% at week 12 (absolute delta +12.2%), with 7 of 12 patients (58%) achieving ≥20% HbF — a threshold historically linked to clinical protection.
Progression Toward Pancellularity
F-cell percentage approximately doubled from ~31% to 63% at week 12, indicating broader distribution of HbF across red cells and potential for increased cellular protection over time.
Marked Improvements in Hemolysis Biomarkers
LDH fell ~34% and indirect bilirubin fell ~40% at week 12, consistent with reduced hemolysis following HbF induction.
Improvement in Erythropoiesis and Hemoglobin
Reticulocytes decreased by ~42% (less bone marrow stress) and mean total hemoglobin rose by ~1.1 g/dL at 20 mg after 12 weeks (compared with ~0.9 g/dL at 12 mg).
Encouraging VOC Trend in Short-Term Data
Based on baseline rates the cohort would have been expected to experience ~16 VOCs over 12 weeks; during the treatment period the PD analysis subset observed 6 VOCs in 5 patients and 7 of 12 patients reported no VOCs during treatment, an encouraging early signal (study not powered for VOCs).
Generally Well Tolerated Safety Profile
No treatment-related serious adverse events reported at 20 mg, three treatment-related adverse events resolved with continued dosing, and no treatment-related discontinuations; pociredir has now been dosed in ~150 adults to date.
Dose Selection and Pharmacodynamic Rationale
Pharmacodynamic data (HBG mRNA induction) showed dose-responsive effects up to 20 mg but not from 20→30 mg in earlier studies, supporting 20 mg as the dose to take forward into regulatory discussions.
Regulatory and Development Progress
Planned FDA end-of-Phase meeting (minutes expected Q2 2026), intent to initiate a potential registration-enabling trial in H2 2026, EMA protocol assistance engagement mid-2026, and activation of an open-label extension to assess longer-term safety/durability.
FULC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FULC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $10.89 | $8.58 | -21.21% |
Oct 29, 2025 | $10.00 | $9.36 | -6.40% |
Jul 29, 2025 | $7.81 | $7.59 | -2.82% |
May 01, 2025 | $3.85 | $4.38 | +13.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Fulcrum Therapeutics (FULC) report earnings?
Fulcrum Therapeutics (FULC) is schdueled to report earning on Apr 30, 2026, Before Open (Confirmed).
What is Fulcrum Therapeutics (FULC) earnings time?
Fulcrum Therapeutics (FULC) earnings time is at Apr 30, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is FULC EPS forecast?
FULC EPS forecast for the fiscal quarter 2026 (Q1) is -0.3.